Metsera, Inc.
MTSR
Rank in Stocks
#2572
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Share Price
$70.50
Last synced: 2025-11-14
Market Cap
$7.33B
Change (1 day)
0.00%
Change (1 year)
33.60%
Country
US
Trade Metsera, Inc. (MTSR)
Category
Healthcare
Earnings for Metsera, Inc. (MTSR)
Earnings in 2026 TTM: 0
According to Metsera, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Metsera, Inc. from 2023 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2024 | $-218.47M | 362.79% |
| 2023 | $-47.21M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
